ATROVENT

LOE Approaching

ipratropium bromide

NDAINHALATIONSOLUTIONPriority Review
Approved
Sep 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

(parasympatholytic) agent which, based on animal studies, appears to inhibit vagally-mediated reflexes by antagonizing the action of acetylcholine, the transmitter agent released at the neuromuscular junctions in the lung. Anticholinergics prevent the increases in intracellular concentration of…

Clinical Trials (5)

NCT01943552Phase 4Completed

Ipratropium Bromide in Peri-Operative COPD

Started Oct 2013
192 enrolled
Pulmonary Disease, Chronic Obstructive
NCT00911651Phase 4Completed

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Started Jun 2008
6 enrolled
COPD
NCT00239434Phase 3Completed

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Started Jun 2003
200 enrolled
Pulmonary Disease, Chronic Obstructive
NCT02238210Phase 4Completed

Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy

Started Dec 2002
230 enrolled
Cold
NCT02177253Phase 3Completed

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease

Started Oct 2002
1,118 enrolled
Pulmonary Disease, Chronic Obstructive